J&J COVID-19 vaccine reviewed for links to additional reports of severe side effects—CDC | Inquirer News

J&J COVID-19 vaccine reviewed for links to additional reports of severe side effects—CDC

/ 11:18 AM April 20, 2021

J&J COVID-19 vaccine reviewed for links to additional reports of severe side effects—CDC

Nurse Nicole McCurrach, 48, draws up coronavirus disease (COVID-19) vaccinations at Richmond raceway in Richmond, Virginia, U.S., March 4, 2021. REUTERS/Julia Rendleman/File Photo

The United States is reviewing reports of a handful of potential cases of severe side effects among people who received Johnson & Johnson’s COVID-19 vaccine, in addition to those that led to a pause in its use, a top U.S. public health official said on Monday.

U.S. health regulators called for a pause in administering the J&J vaccine last week due to reports of serious brain blood clots in six women under age 50 who received the shot out of some 7 million vaccinated with it in the United States.

ADVERTISEMENT

“We are encouraged that it hasn’t been an overwhelming number of cases but we’re looking and seeing what’s come in,” U.S. Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky said during a Monday news briefing.

FEATURED STORIES

The U.S. Food and Drug Administration (FDA) is monitoring the U.S. government’s database for additional reports of side effects, she added. Walensky did not provide any details on the nature of the additional side effects.

An advisory panel for the CDC is meeting on Friday to review data on severe side effects and will make a recommendation on whether the United States should resume using the J&J vaccine.

Public health experts have predicted a resumption, but only after healthcare providers are given clear guidelines for how to recognize and treat the blood clots that can emerge as a rare side effect of the vaccine.

J&J’s COVID-19 vaccine production ramp up may still move more slowly than originally projected. The FDA has postponed authorization of a large J&J vaccine plant in the United States because of factory errors that ruined millions of doses last month.

White House COVID-19 adviser Andy Slavitt on Monday assured Americans that vaccine supply remains robust and that “it has never been easier” for Americans to obtain a vaccine. More than 3 million COVID-19 shots are going into arms each day in the United States using the Pfizer Inc/BioNTech and Moderna Inc two-dose vaccines.

Wealthy governments are looking to COVID-19 shots from Pfizer and Moderna to keep their vaccination programs on track amid mounting concerns about shots from J&J and AstraZeneca Plc.

ADVERTISEMENT

Over 260 million COVID-19 shots have been shipped in the United States and nearly 210 million doses have been given, according to CDC data last updated on Sunday.

Walensky said that of the 84 million people who have been fully vaccinated in the United States, fewer than 6,000 have gotten sick with COVID-19 more than two weeks after being fully dosed. Of those, nearly 400 were hospitalized and around 75 died, according to CDC data. Some of the hospitalizations and deaths were not due to COVID-19 infections.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

“It still makes a really important point. These vaccines are working,” Walensky said.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: CDC, COVID-19, COVID-19 Vaccine

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.